1 Harbord M, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management" 11 : 769-784, 2017
2 Sandborn WJ, "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis" 146 : 85-95, 2014
3 Daperno M, "Review article : medical treatment of severe ulcerative colitis" 16 (16): 7-12, 2002
4 Turner D, "Response to corticosteroids in severe ulcerative colitis : a systematic review of the literature and a meta-regression" 5 : 103-110, 2007
5 Beigel F, "Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members" 9 : e93498-, 2014
6 Verstockt S, "Oncostatin M is a biomarker of diagnosis, worse disease prognosis, and therapeutic nonresponse in inflammatory bowel disease" 27 : 1564-1575, 2021
7 West NR, "Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease" 23 : 579-589, 2017
8 Williams JG, "Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial" 1 : 15-24, 2016
9 Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis" 353 : 2462-2476, 2005
10 Gibson DJ, "CRP/albumin ratio : an early predictor of steroid responsiveness in acute severe ulcerative colitis" 52 : e48-e52, 2018